反応式
[Cl:1][C:2]1[S:6][C:5]([C:7]2[O:11][N:10]=[C:9]([CH2:12][N:13]3[CH:17]=[CH:16][N:15]=[CH:14]3)[CH:8]=2)=[CH:4][CH:3]=1.CCN(CC)CC.ClC(Cl)(Cl)[C:27](Cl)=[O:28].Cl.Cl.[CH:34]([N:37]1[CH2:42][CH2:41][CH:40]([NH2:43])[CH2:39][CH2:38]1)([CH3:36])[CH3:35]>C(Cl)Cl>[CH:34]([N:37]1[CH2:42][CH2:41][CH:40]([NH:43][C:27]([C:14]2[N:13]([CH2:12][C:9]3[CH:8]=[C:7]([C:5]4[S:6][C:2]([Cl:1])=[CH:3][CH:4]=4)[O:11][N:10]=3)[CH:17]=[CH:16][N:15]=2)=[O:28])[CH2:39][CH2:38]1)([CH3:36])[CH3:35]参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 0 °C
実験手順
To a solution of 5-(5-Chloro-thiophen-2-yl)-3-imidazol-1-ylmethyl-isoxazole (85 mg) and NEt3 (89 μL) in DCM (3 mL) was added trichloroacetyl chloride (43 μL) dropwise at 0° C. The mixture was stirred for 5 min at 0° C. and for 30 min at RT. More NEt3 (133 μL) and 1-isopropyl-piperidin-4-ylamine dihydrochloride (88 mg) were added and stirring was continued for 2 h at RT. The mixture was concentrated and the residue was purified by preparative HPLC. The fractions containing the product were evaporated to provide 67 mg of the title compound as its trifluoroacetate salt. MS (ESI+): mi/e=434, chloro pattern.
後処理
- stirringstirring
- waitwas continued for 2 h at RT
- concentrationThe mixture was concentrated
- customthe residue was purified by preparative HPLC
- additionThe fractions containing the product
- customwere evaporated
出典と根拠
- ORDレコード
- ord-855567cfc5f248899cc0bf9c88d2e0b3
- 出典データセット
- uspto-grants-2008_04
- 特許番号
- US07358268B2
関連ノート
読み込み中…